Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Late adverse effects and quality of life in survivors of testicular germ cell tumour

    Research output: Contribution to journalReviewResearchpeer-review

  4. Adverse health behaviours in long-term testicular cancer survivors: a Danish nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Yahia Al-Jebari
  • Ingrid Glimelius
  • Carina Berglund Nord
  • Gabriella Cohn-Cedermark
  • Olof Ståhl
  • Torgrim Tandstad
  • Allan Jensen
  • Hege Sagstuen Haugnes
  • Gedske Daugaard
  • Lars Rylander
  • Aleksander Giwercman
View graph of relations

BACKGROUND: Because of the potential mutagenic effects of chemo- and radiotherapy, there is concern regarding increased risk of congenital malformations (CMs) among children of fathers with cancer. Previous register studies indicate increased CM risk among children conceived after paternal cancer but lack data on oncological treatment. Increased CM risk was recently reported in children born before paternal cancer. This study aims to investigate whether anti-neoplastic treatment for testicular germ-cell cancer (TGCC) implies additional CM risk.

METHODS AND FINDINGS: In this nationwide register study, all singletons born in Sweden 1994-2014 (n = 2,027,997) were included. Paternal TGCC diagnoses (n = 2,380), anti-neoplastic treatment, and offspring CMs were gathered from the Swedish Norwegian Testicular Cancer Group (SWENOTECA) and the Swedish Medical Birth Register. Children were grouped based on +/- paternal TGCC; treatment regimen: surveillance (n = 1,340), chemotherapy (n = 2,533), or radiotherapy (n = 360); and according to time of conception: pre- (n = 2,770) or post-treatment (n = 1,437). Odds ratios (ORs) for CMs were calculated using logistic regression with adjustment for parental ages, maternal body mass index (BMI), and maternal smoking. Children conceived before a specific treatment acted as reference for children conceived after the same treatment. Among children fathered by men with TGCC (n = 4,207), 184 had a CM. The risk of malformations was higher among children of fathers with TGCC compared with children fathered by men without TGCC (OR 1.28, 95% confidence interval [CI] 1.19-1.38, p = 0.001, 4.4% versus 3.5%). However, no additional risk increase was associated with oncological treatment when comparing post-treatment-to pretreatment-conceived children (chemotherapy, OR = 0.82, 95% CI 0.54-1.25, p = 0.37, 4.1% versus 4.6%; radiotherapy, OR = 1.01, 95% CI 0.25-4.12, p = 0.98, 3.2% versus 3.0%). Study limitations include lack of data on use of cryopreserved or donor sperm and on seminoma patients for the period 1995-2000-both tending to decrease the difference between the groups with TGCC and without TGCC. Furthermore, the power of analyses on chemotherapy intensity and radiotherapy was limited.

CONCLUSIONS: No additional increased risk of CMs was observed in children of men with TGCC treated with radio- or chemotherapy. However, paternal TGCC per se was associated with modestly increased risk for offspring malformations. Clinically, this information can reassure concerned patients.

Original languageEnglish
Article numbere1002816
JournalPLOS Medicine
Volume16
Issue number6
Pages (from-to)e1002816
ISSN1549-1277
DOIs
Publication statusPublished - 1 Jun 2019

ID: 57752075